Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …

Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Background: Diabetic retinopathy is a leading cause of visual impairment in working-age
adults worldwide. Duration of diabetes is a major risk factor associated with the development …

The global burden of diabetic retinopathy (DR) continues to worsen and DR remains a
leading cause of vision loss worldwide. Here, we describe an algorithm to predict DR …

Importance Panretinal photocoagulation (PRP) is the standard treatment for reducing severe
visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina …

Purpose To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330),
trials of ranibizumab in diabetic macular edema (DME). Design Phase III, randomized …

OBJECTIVE To evaluate the association between initial diabetic retinopathy (DR)
severity/risk of blindness in patients with newly diagnosed DR/good vision in the US …

Diabetic retinopathy remains as a leading cause of blindness in developed countries.
Current treatments target late stages of DR when vision has already been significantly …

Diabetic retinopathy (DR) impairs vision of patients with type 1 and type 2 diabetes,
associated with vascular dysfunction and occlusion, retinal edema, hemorrhage, and …

Importance Anti–vascular endothelial growth factor (VEGF) therapy is commonly used to
treat numerous retinal conditions and appears safe, yet controversy remains regarding …